Briggs Morrison, Syndax Pharmaceuticals CEO (Syndax)
April 20, 2021 11:07 AM EDTUpdated 04:01 PM
R&D

Syn­dax looks to re­bound from sting­ing late-stage fail­ure, un­cork­ing ear­ly da­ta for next can­cer drug up

Nicole DeFeudis

Editor

A year ago, Syn­dax Phar­ma­ceu­ti­cals suf­fered a ma­jor Phase III flop that forced it to for­go an FDA fil­ing for its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

A service from the Financial Times